5:30 AM - 5:40 AM Welcome and Introduction Gerard A. Silvestri, MD, MS
5:40 AM - 6:00 AM Stage III NSCLC: Background
- Diagnosis, staging, and referral – Gerard A. Silvestri, MD, MS
- Current paradigms for definitive concurrent CRT – Mark A. Socinski, MD
- Radiation therapy considerations and rationale for combining with immunotherapy – Kristin Higgins, MD
6:00 AM - 6:10 AM Approved Immune Checkpoint Inhibitors in the Treatment of Stage III NSCLC
Mark A. Socinski, MD
6:10 AM - 6:40 AM Case Discussions on Optimal Integration of Checkpoint Inhibitors into the Management of Stage III NSCLC
Panel: Gerard A. Silvestri, MD, MS (Moderator); Kristin Higgins, MD; Mark A. Socinski, MD
6:40 AM - 6:55 AM Specialty Viewpoints: Working Effectively With the Clinical Care Team Through Shared Knowledge
- Pulmonology – Gerard A. Silvestri, MD, MS
- Radiation Oncology – Kristin Higgins, MD
- Medical Oncology – Mark A. Socinski, MD
6:55 AM - 7:00 AM Panel Discussion and Audience Question and Answer Session
Gerard Silvestri, MD, MS
Professor of Medicine
Division of Pulmonary and Critical Care Medicine
Medical University of South Carolina
Charleston, South Carolina
Kristin Higgins, MD
Department of Radiation Oncology
Mark A. Socinski, MD
Executive Medical Director
Member, Thoracic Oncology Program
Florida Hospital Cancer Institute
The goal of this activity is to improve the knowledge, confidence, and competence of pulmonologists, oncology specialists, and other clinicians to integrate immune checkpoint inhibitors into treatment of their patients with stage III non-small-cell lung cancer.
This program is intended for pulmonologists and other healthcare providers who care for patients with non-small-cell lung cancer.
- Discuss the biologic rationale for using immune checkpoint inhibitors in patients with locally advanced NSCLC
- Plan optimal, individualized therapeutic strategies, including whether to pursue resection, for patients with stage III NSCLC, considering the available clinical evidence, expert recommendations, and patient preferences
- Identify subsets of patients with stage III NSCLC most likely to benefit from durvalumab consolidation after definitive platinum-based chemotherapy and concurrent radiation therapy
- Identify subsets of patients with stage III NSCLC most likely to benefit from pembrolizumab
- Describe ways that the use of immunotherapy in earlier stages of disease may require a different understanding of risk/benefit and applicable subsets of patients
- Manage immune-mediated adverse events with the use of automated decision support resources and guidelines
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Board of Pathology Continuing Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Lifelong Learning (Part II) and Self-Assessment Module (SAM) points in the American Board of Pathology's Maintenance of Certification (MOC) Program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABPath Continuing Certification (formerly Maintenance of Certification or MOC) credit.
If you are interested in having us report ABPath MOC, please ensure the following information is provided within your Member Profile:
Name - as registered with ABPath
Date of Birth (Month/Day)
Your ABPath ID number
Learners must complete the post-test with a passing score of 70% and provide additional documentation following the symposium.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.